MCID: THR014
MIFTS: 64

Thrombocytopenia

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia

Summaries for Thrombocytopenia

PubMed Health : 63 About thrombocytopenia: Thrombocytopenia (THROM-bo-si-to-PE-ne-ah) is a condition in which your blood has a lower than normal number of blood cell fragments called platelets (PLATE-lets).Platelets are made in your bone marrow along with other kinds of blood cells. They travel through your blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes (THROM-bo-sites) because a clot also is called a thrombus.

MalaCards based summary : Thrombocytopenia is related to thrombocytopenia 1 and thrombocytopenia-absent radius syndrome. An important gene associated with Thrombocytopenia is ETV6 (ETS Variant 6), and among its related pathways/superpathways are Tight junction and Response to elevated platelet cytosolic Ca2+. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and bone marrow, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A blood platelet disease characterized by low a platelet count in the blood.

Wikipedia : 76 Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as... more...

Related Diseases for Thrombocytopenia

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia Ankrd26-Related Thrombocytopenia
Myh9 Related Thrombocytopenia

Diseases related to Thrombocytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 789)
# Related Disease Score Top Affiliating Genes
1 thrombocytopenia 1 34.3 GATA1 HOXA11 WAS
2 thrombocytopenia-absent radius syndrome 34.1 ANKRD26 GATA1 GP1BA MPL
3 thrombocytopenia 2 34.0 ANKRD26 MASTL MECOM
4 thrombocytopenia due to platelet alloimmunization 33.6 GP9 ITGA2 ITGA2B ITGB3 MPL MYH9
5 fetal and neonatal alloimmune thrombocytopenia 33.5 GP1BA GP1BB ITGA2 ITGA2B ITGB3
6 autosomal thrombocytopenia with normal platelets 33.5 CYCS MASTL
7 radio-ulnar synostosis-amegakaryocytic thrombocytopenia syndrome 33.2 HOXA11 MECOM
8 thrombocytopenic purpura, autoimmune 33.0 GP1BA IL11 ITGA2B ITGB3 MPL
9 primary thrombocytopenia 33.0 ADAMTS13 GP1BA ITGA2 ITGA2B ITGB3 MPL
10 platelet disorder, familial, with associated myeloid malignancy 32.5 ANKRD26 ETV6
11 gray platelet syndrome 32.2 GATA1 GP9 MASTL
12 myh-9 related disease 32.1 ANKRD26 GP1BA MYH9
13 bernard-soulier syndrome 32.0 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
14 aplastic anemia 31.8 GATA1 IL11 ITGA2B MPL
15 blood platelet disease 30.9 ADAMTS13 GP1BA GP1BB GP9 ITGA2B ITGB3
16 purpura 30.5 ADAMTS13 GP1BB ITGA2B ITGB3 MPL
17 myelodysplastic syndrome 30.4 ETV6 GATA1 IL11 MECOM MPL
18 bleeding disorder, platelet-type, 16 30.2 ITGA2B ITGB3
19 leukemia, acute myeloid 30.0 ETV6 GATA1 MECOM MPL
20 autosomal dominant macrothrombocytopenia 29.8 GP1BA GP1BB ITGA2B ITGB3 MYH9
21 essential thrombocythemia 29.8 GATA1 GP1BA IL11 ITGA2B ITGB3 MPL
22 leukemia, chronic myeloid 29.8 ETV6 GATA1 MECOM MPL
23 thrombasthenia 29.8 GP1BA GP9 ITGA2 ITGA2B ITGB3
24 myocardial infarction 29.6 ADAMTS13 GP1BA ITGA2 ITGA2B ITGB3
25 glanzmann thrombasthenia 29.6 GP1BA GP9 ITGA2 ITGA2B ITGB3
26 megakaryocytic leukemia 29.4 GATA1 IL11 ITGA2B
27 hemorrhagic cystitis 29.3 CYCS IL11
28 amegakaryocytic thrombocytopenia, congenital 12.6
29 heparin-induced thrombocytopenia 12.6
30 thrombocytopenia, paris-trousseau type 12.5
31 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 12.5
32 thrombocytopenia with beta-thalassemia, x-linked 12.4
33 dyserythropoietic anemia and thrombocytopenia 12.4
34 thrombocytopenia 4 12.4
35 hemangioma-thrombocytopenia syndrome 12.4
36 thrombocytopenia, x-linked, with or without dyserythropoietic anemia 12.4
37 thrombocytopenia 5 12.3
38 acquired amegakaryocytic thrombocytopenia 12.3
39 thrombocytopenia 3 12.3
40 thrombocytopenia 6 12.3
41 radioulnar synostosis with amegakaryocytic thrombocytopenia 2 12.3
42 acquired thrombocytopenia 12.3
43 myh9 related thrombocytopenia 12.2
44 thrombocytopenia, anemia, and myelofibrosis 12.2
45 thrombocytopenia, cyclic 12.2
46 multifocal lymphangioendotheliomatosis with thrombocytopenia 12.1
47 thrombocytopenia robin sequence 12.1
48 transient neonatal thrombocytopenia 12.1
49 ankrd26-related thrombocytopenia 12.1
50 wiskott-aldrich syndrome 12.0

Graphical network of the top 20 diseases related to Thrombocytopenia:



Diseases related to Thrombocytopenia

Symptoms & Phenotypes for Thrombocytopenia

MGI Mouse Phenotypes related to Thrombocytopenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 CYCS ETV6 GATA1 GP1BA HOXA11 ITGA2
2 hematopoietic system MP:0005397 10.03 ACBD5 ADAMTS13 CYCS ETV6 GATA1 GP1BA
3 embryo MP:0005380 9.91 CYCS ETV6 GATA1 ITGA2B ITGB3 MASTL
4 homeostasis/metabolism MP:0005376 9.77 ADAMTS13 ANKRD26 ETV6 GATA1 GP1BA GP1BB
5 immune system MP:0005387 9.36 ACBD5 ADAMTS13 CYCS ETV6 GATA1 ITGA2B

Drugs & Therapeutics for Thrombocytopenia

PubMedHealth treatment related to Thrombocytopenia: 63

Treatment for thrombocytopenia depends on its cause and severity. The main goal of treatment is to prevent death and disability caused by bleeding.If your condition is mild, you may not need treatment. A fully normal platelet count isn't necessary to prevent bleeding, even with severe cuts or accidents.Thrombocytopenia often improves when its underlying cause is treated. People who inherit the condition usually don't need treatment.If a reaction to a medicine is causing a low platelet count, your doctor may prescribe another medicine. Most people recover after the initial medicine has been stopped. For heparin-induced thrombocytopenia (HIT), stopping the heparin isn't enough. Often, you'll need another medicine to prevent blood clotting.If your immune system is causing a low platelet count, your doctor may prescribe medicines to suppress the immune system.

Drugs for Thrombocytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 730)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
3 Certoparin Approved, Investigational Phase 4,Phase 3
4
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
5
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
6
Ribavirin Approved Phase 4,Phase 2,Phase 3 36791-04-5 37542
7
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
8
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 1 128270-60-0 16129704
9
Clopidogrel Approved Phase 4,Phase 3,Phase 2 113665-84-2, 120202-66-6 60606
10
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
11
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 616-91-1 12035
12
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
13
Calcium Carbonate Approved, Investigational Phase 4,Phase 3 471-34-1
14
Hydroxychloroquine Approved Phase 4,Phase 3 118-42-3 3652
15
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 446-86-6 2265
16
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
17
Oprelvekin Approved, Investigational Phase 4,Phase 2,Phase 3 145941-26-0
18
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
19
Enoxaparin Approved Phase 4,Phase 2,Phase 3 9005-49-6 772
20
Fluorouracil Approved Phase 4,Phase 3,Phase 1,Phase 2 51-21-8 3385
21
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
22
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
23
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
24
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
25
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
26
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
27
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
28
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
31
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 82410-32-0 3454
32
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 175865-60-8 64147
33
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
34
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3 26787-78-0 33613
35
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
36
Clarithromycin Approved Phase 4,Phase 2,Phase 3 81103-11-9 84029
37
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3 7487-88-9 24083
38
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 1 99-66-1 3121
39
Tinzaparin Approved Phase 4 9005-49-6, 9041-08-1 25244225
40
Fondaparinux Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104993-28-4
41 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
42
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
43
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 216503-57-0
44
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
45
Linezolid Approved, Investigational Phase 4,Phase 1,Phase 2 165800-03-3 441401
46
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
47
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
48
Fludarabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
49
Argatroban Approved, Investigational Phase 4,Phase 3,Phase 2 74863-84-6 152951
50
Abciximab Approved Phase 4,Phase 3 143653-53-6

Interventional clinical trials:

(show top 50) (show all 1620)
# Name Status NCT ID Phase Drugs
1 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 The HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
3 Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Unknown status NCT02355873 Phase 4
4 Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
5 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4 Neurobion;placebo
6 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
7 Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI Unknown status NCT00476944 Phase 4
8 Impact of Heparin on the Need for Mechanical Ventilation in Neonates Unknown status NCT00196469 Phase 4 heparin
9 Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing Unknown status NCT01456364 Phase 4 Ticagrelor;Prasugrel
10 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
11 Low Dose Calcium to Prevent Preeclampsia Unknown status NCT02338687 Phase 4
12 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
13 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
14 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
15 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
16 Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients Completed NCT00759083 Phase 4 bivalirudin
17 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
18 Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin Completed NCT00039858 Phase 4 Argatroban
19 High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
20 Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion Completed NCT01955811 Phase 4 Administration of platelet concentrate and taking blood samples
21 Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process Completed NCT01789762 Phase 4
22 EArly Discharge After Transradial Stenting of CoronarY Arteries: The EASY Study Completed NCT00169819 Phase 4 Abciximab
23 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
24 Enoxaparin Versus Unfractionated Heparin in PCI Completed NCT00439855 Phase 4 Enoxaparin i.v.;unfractionated heparin
25 Nadroparin for the Initial Treatment of Pulmonary Thromboembolism Completed NCT00796692 Phase 4 Nadroparin;Unfractionated heparin(UFH)
26 Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3) Completed NCT00133250 Phase 4 Abciximab
27 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
28 Study to Evaluate the Mortality Reduction of Enoxaparin in Hospitalized Acutely Ill Medical Receiving Enoxaparin Completed NCT00622648 Phase 4 Enoxaparin;Placebo
29 EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization Completed NCT00077753 Phase 4 enoxaparin sodium
30 Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients Completed NCT03114995 Phase 4 Tirofiban
31 Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation Completed NCT00943228 Phase 4 mycophenolate mofetil
32 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
33 Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis Completed NCT02215993 Phase 4 Prasugrel;Ticagrelor
34 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
35 Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
36 Efficacy of Abciximab Bolus Only Regimen in Providing Inhibition of Platelet Action Over Time Completed NCT00929279 Phase 4 bolus+infusion;abciximab bolus only regimen
37 Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement Completed NCT00362492 Phase 4
38 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
39 Safety Study of Desirudin, an Anticoagulant for the Prophylaxis of Thrombosis Completed NCT00913133 Phase 4 Desirudin
40 VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Completed NCT01684813 Phase 4 Prasugrel.;Clopidogrel
41 Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients Completed NCT00895583 Phase 4 Tacrolimus;Sirolimus;Tacrolimus
42 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) Completed NCT01585324 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus]
43 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
44 BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial. Completed NCT01696110 Phase 4 Bivalirudin;heparin;heparin plus tirofiban
45 How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention Completed NCT01519518 Phase 4 unfractionated heparin;Bivalirudin
46 Once-a-day Immunosuppression(CISECON_a_day) Completed NCT01964014 Phase 4 advagrf
47 DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) Completed NCT01743521 Phase 4 TPV/PEG-IFN/RBV
48 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
49 Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD Completed NCT02681172 Phase 4 Neuraceq (florbetaben 18F)
50 Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance Completed NCT00400400 Phase 4 Enteric-coated mycophenolate sodium (EC-MPS);Mycophenolate mofetil;Placebo to mycophenolate sodium;Placebo to mycophenolate mofetil

Search NIH Clinical Center for Thrombocytopenia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Thrombocytopenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: thrombocytopenia

Genetic Tests for Thrombocytopenia

Genetic tests related to Thrombocytopenia:

# Genetic test Affiliating Genes
1 Thrombocytopenia 29

Anatomical Context for Thrombocytopenia

MalaCards organs/tissues related to Thrombocytopenia:

41
Liver, Bone, Bone Marrow, Testes, Myeloid, T Cells, B Cells

Publications for Thrombocytopenia

Articles related to Thrombocytopenia:

(show top 50) (show all 4878)
# Title Authors Year
1
Association of cytotoxic T-lymphocyte antigen 4 gene with immune thrombocytopenia in Chinese Han children. ( 30319055 )
2019
2
Increased GPIbα shedding from platelets treated with immune thrombocytopenia plasma. ( 30445311 )
2019
3
Role of antithyroid autoimmunity as a predictive biomarker of chronic immune thrombocytopenia. ( 30270575 )
2019
4
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. ( 29226426 )
2018
5
Retrospective analysis of the risk of hemorrhage associated with moderate and severe thrombocytopenia of 173 patients with systemic lupus erythematosus. ( 29979417 )
2018
6
Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). ( 29632238 )
2018
7
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. ( 29958825 )
2018
8
A Case of Posterior Circulation Ischemic Stroke Caused by Heparin-Induced Thrombocytopenia after Detaining Hepatic Arterial Infusion Catheter. ( 29859863 )
2018
9
Kinetics of viral load and cytokines in severe fever with thrombocytopenia syndrome. ( 29427908 )
2018
10
Differential Expression of MiR-106b-5p and MiR-200c-3p in Newly Diagnosed Versus Chronic Primary Immune Thrombocytopenia Patients Based on Systematic Analysis. ( 29402802 )
2018
11
Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss? ( 29164662 )
2018
12
High ANTI-PF4/Heparin Antibodies Titer and Thromboses Due to Infection 9 Months After Cessation of Heparin in Hemodialyzed Patient With Heparin-Induced Thrombocytopenia. ( 29856115 )
2018
13
Reduced PTEN involved in primary immune thrombocytopenia via contributing to B cell hyper-responsiveness. ( 29175594 )
2018
14
Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-I_B/SMAD pathway in patients with immune thrombocytopenia. ( 29327472 )
2018
15
Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. ( 29914979 )
2018
16
Intracranial hemorrhages in neonates born from 32 weeks of gestation-low frequency of associated fetal and neonatal alloimmune thrombocytopenia: a register-based study. ( 29119564 )
2018
17
Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions. ( 29421832 )
2018
18
Evaluating Thrombocytopenia During Heparin Therapy. ( 29411014 )
2018
19
IL-10 polymorphisms and T-cell subsets could affect the clinical presentation and outcome of childhood immune thrombocytopenia in Egyptian population. ( 29696721 )
2018
20
Adding to the complexity of fetal and neonatal alloimmune thrombocytopenia: Reduced fibrinogen binding in the presence of anti-HPA-1a antibody and hypo-responsive neonatal platelets. ( 29306729 )
2018
21
Cissus quadrangularis-Induced Thrombocytopenia in a Renal Allograft Recipient. ( 29957161 )
2018
22
A patient with severe fever with thrombocytopenia syndrome and hemophagocytic lymphohistiocytosis-associated involvement of the central nervous system. ( 29138019 )
2018
23
TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. ( 29468524 )
2018
24
Abciximab/Heparin During Acute Heparin-induced Thrombocytopenia: A Word of Caution (Reply). ( 29371038 )
2018
25
Case 4-2018: A Newborn with Thrombocytopenia, Cataracts, and Hepatosplenomegaly. ( 29414276 )
2018
26
The impact of acquired thrombocytopenia on long-term outcomes of patients undergoing elective percutaneous coronary intervention: An analysis of 8,271 consecutive patients. ( 29368387 )
2018
27
Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation. ( 29903887 )
2018
28
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. ( 29357781 )
2018
29
Leukemic mature B-cell neoplasm observed during the treatment with romiplostim in patient with thrombocytopenia and liver cirrhosis. ( 29881570 )
2018
30
Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia in Thymoma. ( 29713553 )
2018
31
Neonatal Alloimmune Thrombocytopenia With Amegakaryocytosis, B Lymphopenia, and Villitis. ( 29610181 )
2018
32
Left ventricular assist device implantation after plasma exchange for heparin-induced thrombocytopenia. ( 29938391 )
2018
33
Partial splenic embolization in the treatment of prolonged thrombocytopenia due to hypersplenism in metastatic cancer patients. ( 29696427 )
2018
34
Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus. ( 29380254 )
2018
35
Lurasidone Induced Thrombocytopenia: Is it a Signal of Drug Induced Myelosuppression? ( 29962579 )
2018
36
A MECOM variant in an African American child with radioulnar synostosis and thrombocytopenia. ( 29200407 )
2018
37
Outcomes of Endoscopic Intervention for Overt Gastrointestinal Bleeding in Severe Thrombocytopenia. ( 29408558 )
2018
38
Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. ( 29442265 )
2018
39
Subacute sclerosing panencephalitis and immune thrombocytopenia: More than a coincidence? ( 29407001 )
2018
40
Phlegmasia Cerulea Dolens Following Heparin-Induced Thrombocytopenia. ( 29422736 )
2018
41
Thrombopoietin and its receptor expression in pediatric patients with chronic immune thrombocytopenia. ( 29313460 )
2018
42
Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. ( 29409729 )
2018
43
Heparin-induced thrombocytopenia complicating extracorporeal membrane oxygenation support in pediatric patients: review of the literature and alternative anticoagulants. ( 29788841 )
2018
44
Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study. ( 29934777 )
2018
45
Disseminated Porokeratosis with Idiopathic Thrombocytopenia - Case Report and Literature Review of Porokeratosis and Related Disorders. ( 29484012 )
2018
46
Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). ( 29429054 )
2018
47
Evaluation of the Incidence of Ibuprofen Administration in Alcohol and Opioid Detoxification Patients With Concomitant Thrombocytopenia. ( 29434386 )
2018
48
Autoantibody against integrin I+<sub>v</sub> I^<sub>3</sub> contributes to thrombocytopenia by blocking the migration and adhesion of megakaryocytes. ( 29953749 )
2018
49
Usefulness of thrombopoietin receptor agonists for persistent clinically-relevant thrombocytopenia after allogeneic stem cell transplantation. ( 29956377 )
2018
50
Diminished expression of I^2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. ( 29350259 )
2018

Variations for Thrombocytopenia

ClinVar genetic disease variations for Thrombocytopenia:

6 (show top 50) (show all 427)
# Gene Variation Type Significance SNP ID Assembly Location
1 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh38 Chromosome 12, 11869601: 11869601
2 ETV6 NM_001987.4(ETV6): c.641C> T (p.Pro214Leu) single nucleotide variant Pathogenic/Likely pathogenic rs724159947 GRCh37 Chromosome 12, 12022535: 12022535
3 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh38 Chromosome 12, 11884541: 11884541
4 ETV6 NM_001987.4(ETV6): c.1106G> A (p.Arg369Gln) single nucleotide variant Pathogenic rs724159946 GRCh37 Chromosome 12, 12037475: 12037475
5 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh37 Chromosome 12, 12038902: 12038902
6 ETV6 NM_001987.4(ETV6): c.1195C> T (p.Arg399Cys) single nucleotide variant Pathogenic rs724159945 GRCh38 Chromosome 12, 11885968: 11885968
7 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh37 Chromosome 12, 12038855: 12038859
8 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh38 Chromosome 12, 11885921: 11885925
9 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh37 Chromosome 12, 12037415: 12037415
10 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh38 Chromosome 12, 11884481: 11884481
11 COL4A4 NM_000092.4(COL4A4): c.4217-15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs200926310 GRCh37 Chromosome 2, 227877028: 227877028
12 COL4A4 NM_000092.4(COL4A4): c.4217-15T> C single nucleotide variant Conflicting interpretations of pathogenicity rs200926310 GRCh38 Chromosome 2, 227012312: 227012312
13 CYCS NM_018947.5(CYCS): c.-6T> G single nucleotide variant Benign/Likely benign rs11267038 GRCh37 Chromosome 7, 25163744: 25163744
14 CYCS NM_018947.5(CYCS): c.-6T> G single nucleotide variant Benign/Likely benign rs11267038 GRCh38 Chromosome 7, 25124125: 25124125
15 ANKRD26 NM_014915.2(ANKRD26): c.4542T> A (p.Phe1514Leu) single nucleotide variant Benign/Likely benign rs2274741 GRCh37 Chromosome 10, 27303605: 27303605
16 ANKRD26 NM_014915.2(ANKRD26): c.4542T> A (p.Phe1514Leu) single nucleotide variant Benign/Likely benign rs2274741 GRCh38 Chromosome 10, 27014676: 27014676
17 ANKRD26 NM_014915.2(ANKRD26): c.4145T> A (p.Phe1382Tyr) single nucleotide variant Benign/Likely benign rs78251061 GRCh38 Chromosome 10, 27022628: 27022628
18 ANKRD26 NM_014915.2(ANKRD26): c.4145T> A (p.Phe1382Tyr) single nucleotide variant Benign/Likely benign rs78251061 GRCh37 Chromosome 10, 27311557: 27311557
19 ANKRD26 NM_014915.2(ANKRD26): c.3972+3A> G single nucleotide variant Benign/Likely benign rs72807627 GRCh38 Chromosome 10, 27028849: 27028849
20 ANKRD26 NM_014915.2(ANKRD26): c.3972+3A> G single nucleotide variant Benign/Likely benign rs72807627 GRCh37 Chromosome 10, 27317778: 27317778
21 ANKRD26 NM_014915.2(ANKRD26): c.3913G> A (p.Val1305Ile) single nucleotide variant Benign/Likely benign rs10829163 GRCh38 Chromosome 10, 27028911: 27028911
22 ANKRD26 NM_014915.2(ANKRD26): c.3913G> A (p.Val1305Ile) single nucleotide variant Benign/Likely benign rs10829163 GRCh37 Chromosome 10, 27317840: 27317840
23 ANKRD26 NM_014915.2(ANKRD26): c.3658G> C (p.Val1220Leu) single nucleotide variant Benign/Likely benign rs12572862 GRCh38 Chromosome 10, 27033374: 27033374
24 ANKRD26 NM_014915.2(ANKRD26): c.3658G> C (p.Val1220Leu) single nucleotide variant Benign/Likely benign rs12572862 GRCh37 Chromosome 10, 27322303: 27322303
25 ANKRD26 NM_014915.2(ANKRD26): c.3384G> A (p.Lys1128=) single nucleotide variant Benign/Likely benign rs41299210 GRCh37 Chromosome 10, 27323995: 27323995
26 ANKRD26 NM_014915.2(ANKRD26): c.3384G> A (p.Lys1128=) single nucleotide variant Benign/Likely benign rs41299210 GRCh38 Chromosome 10, 27035066: 27035066
27 ANKRD26 NM_014915.2(ANKRD26): c.2978A> C (p.Glu993Ala) single nucleotide variant Benign/Likely benign rs61745662 GRCh37 Chromosome 10, 27324401: 27324401
28 ANKRD26 NM_014915.2(ANKRD26): c.2978A> C (p.Glu993Ala) single nucleotide variant Benign/Likely benign rs61745662 GRCh38 Chromosome 10, 27035472: 27035472
29 ANKRD26 NM_014915.2(ANKRD26): c.2376-4G> A single nucleotide variant Benign/Likely benign rs75445709 GRCh37 Chromosome 10, 27326987: 27326987
30 ANKRD26 NM_014915.2(ANKRD26): c.2376-4G> A single nucleotide variant Benign/Likely benign rs75445709 GRCh38 Chromosome 10, 27038058: 27038058
31 ANKRD26 NM_014915.2(ANKRD26): c.1596_1598delAGA (p.Glu533del) deletion Benign/Likely benign rs138423863 GRCh37 Chromosome 10, 27342286: 27342288
32 ANKRD26 NM_014915.2(ANKRD26): c.1596_1598delAGA (p.Glu533del) deletion Benign/Likely benign rs138423863 GRCh38 Chromosome 10, 27053357: 27053359
33 ANKRD26 NM_014915.2(ANKRD26): c.1564+6T> C single nucleotide variant Benign/Likely benign rs149655759 GRCh38 Chromosome 10, 27060339: 27060339
34 ANKRD26 NM_014915.2(ANKRD26): c.1564+6T> C single nucleotide variant Benign/Likely benign rs149655759 GRCh37 Chromosome 10, 27349268: 27349268
35 ANKRD26 NM_014915.2(ANKRD26): c.1273A> G (p.Ile425Val) single nucleotide variant Benign/Likely benign rs12359281 GRCh38 Chromosome 10, 27064078: 27064078
36 ANKRD26 NM_014915.2(ANKRD26): c.1273A> G (p.Ile425Val) single nucleotide variant Benign/Likely benign rs12359281 GRCh37 Chromosome 10, 27353007: 27353007
37 ANKRD26 NM_014915.2(ANKRD26): c.1207+15A> G single nucleotide variant Benign/Likely benign rs115864032 GRCh37 Chromosome 10, 27356071: 27356071
38 ANKRD26 NM_014915.2(ANKRD26): c.1207+15A> G single nucleotide variant Benign/Likely benign rs115864032 GRCh38 Chromosome 10, 27067142: 27067142
39 ANKRD26 NM_014915.2(ANKRD26): c.624A> G (p.Val208=) single nucleotide variant Benign/Likely benign rs2297145 GRCh37 Chromosome 10, 27381349: 27381349
40 ANKRD26 NM_014915.2(ANKRD26): c.624A> G (p.Val208=) single nucleotide variant Benign/Likely benign rs2297145 GRCh38 Chromosome 10, 27092420: 27092420
41 ANKRD26 NM_014915.2(ANKRD26): c.59A> G (p.Gln20Arg) single nucleotide variant Benign/Likely benign rs7897309 GRCh37 Chromosome 10, 27389197: 27389197
42 ANKRD26 NM_014915.2(ANKRD26): c.59A> G (p.Gln20Arg) single nucleotide variant Benign/Likely benign rs7897309 GRCh38 Chromosome 10, 27100268: 27100268
43 ANKRD26 NM_014915.2(ANKRD26): c.-59G> A single nucleotide variant Benign/Likely benign rs3737056 GRCh37 Chromosome 10, 27389314: 27389314
44 ANKRD26 NM_014915.2(ANKRD26): c.-59G> A single nucleotide variant Benign/Likely benign rs3737056 GRCh38 Chromosome 10, 27100385: 27100385
45 ANKRD26 NM_014915.2(ANKRD26): c.-140C> G single nucleotide variant Benign/Likely benign rs41299222 GRCh38 Chromosome 10, 27100466: 27100466
46 ANKRD26 NM_014915.2(ANKRD26): c.-140C> G single nucleotide variant Benign/Likely benign rs41299222 GRCh37 Chromosome 10, 27389395: 27389395
47 MASTL NM_032844.4(MASTL): c.-27T> C single nucleotide variant Benign/Likely benign rs7907981 GRCh37 Chromosome 10, 27444329: 27444329
48 MASTL NM_032844.4(MASTL): c.-27T> C single nucleotide variant Benign/Likely benign rs7907981 GRCh38 Chromosome 10, 27155400: 27155400
49 MASTL NM_032844.4(MASTL): c.-12T> G single nucleotide variant Benign/Likely benign rs7907988 GRCh37 Chromosome 10, 27444344: 27444344
50 MASTL NM_032844.4(MASTL): c.-12T> G single nucleotide variant Benign/Likely benign rs7907988 GRCh38 Chromosome 10, 27155415: 27155415

Expression for Thrombocytopenia

Search GEO for disease gene expression data for Thrombocytopenia.

Pathways for Thrombocytopenia

Pathways related to Thrombocytopenia according to KEGG:

37
# Name Kegg Source Accession
1 Tight junction hsa04530

Pathways related to Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.16 GATA1 GP1BA GP1BB GP9 ITGA2 ITGA2B
2
Show member pathways
12.76 ITGA2 ITGA2B ITGB3 MYH9 WAS
3 12.47 ITGA2 ITGA2B ITGB3 MYH9 WAS
4
Show member pathways
12.08 CYCS ITGA2 ITGA2B ITGB3 MYH9 WAS
5
Show member pathways
12.06 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
6 11.89 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
7
Show member pathways
11.86 ITGA2 ITGA2B ITGB3
8 11.71 CYCS ITGA2 ITGA2B
9 11.7 GP1BA IL11 ITGA2 ITGA2B ITGB3 MPL
10 11.65 ITGA2 ITGA2B ITGB3
11 11.47 GP1BB GP9 ITGA2 ITGA2B ITGB3
12 11.46 ITGA2 ITGA2B ITGB3
13 11.42 GATA1 GP9 ITGA2B ITGB3
14
Show member pathways
11.42 GP1BA GP1BB GP9 ITGA2B ITGB3 MPL
15 11.38 ITGA2 ITGA2B ITGB3 MYH9
16 11.24 IL11 ITGA2 ITGA2B ITGB3
17 11.15 GP1BA GP1BB GP9 IL11 ITGA2 ITGA2B
18 10.91 ITGA2B ITGB3
19 10.67 GP1BA GP1BB GP9 ITGA2
20 10.63 GP1BA GP1BB GP9

GO Terms for Thrombocytopenia

Cellular components related to Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.43 ADAMTS13 GP1BA ITGA2 ITGA2B ITGB3 MPL
2 platelet alpha granule membrane GO:0031092 9.16 ITGA2B ITGB3
3 integrin complex GO:0008305 8.8 ITGA2 ITGA2B ITGB3

Biological processes related to Thrombocytopenia according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.91 GP1BA GP1BB GP9 ITGA2 ITGA2B ITGB3
2 cell-matrix adhesion GO:0007160 9.73 ADAMTS13 ITGA2 ITGA2B ITGB3
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.69 GATA1 IL11 ITGB3
4 regulation of megakaryocyte differentiation GO:0045652 9.65 GATA1 GP1BA ITGA2B
5 platelet activation GO:0030168 9.65 ADAMTS13 GP1BA GP1BB GP9 ITGB3
6 hemostasis GO:0007599 9.62 ADAMTS13 GP1BA GP1BB GP9
7 cell adhesion mediated by integrin GO:0033627 9.58 ITGA2 ITGB3
8 actin filament-based movement GO:0030048 9.58 MYH9 WAS
9 blood coagulation, intrinsic pathway GO:0007597 9.58 GP1BA GP1BB GP9
10 platelet formation GO:0030220 9.57 GATA1 MYH9
11 cell-substrate adhesion GO:0031589 9.56 ITGA2 ITGB3
12 blood coagulation GO:0007596 9.56 ADAMTS13 GATA1 GP1BA GP1BB GP9 ITGA2
13 hematopoietic stem cell proliferation GO:0071425 9.55 ETV6 MECOM
14 integrin-mediated signaling pathway GO:0007229 9.55 ADAMTS13 ITGA2 ITGA2B ITGB3 MYH9
15 mesodermal cell differentiation GO:0048333 9.54 ITGA2 ITGB3
16 positive regulation of leukocyte migration GO:0002687 9.52 ITGA2 ITGA2B
17 response to amine GO:0014075 9.49 ADAMTS13 ITGA2
18 megakaryocyte differentiation GO:0030219 9.46 GATA1 IL11
19 platelet aggregation GO:0070527 9.1 GATA1 GP1BA ITGA2B ITGB3 MPL MYH9

Molecular functions related to Thrombocytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinogen binding GO:0070051 8.96 ITGA2B ITGB3
2 integrin binding GO:0005178 8.92 ADAMTS13 ITGA2 ITGB3 MYH9
3 protein binding GO:0005515 10.06 ADAMTS13 ANKRD26 CYCS ETV6 GATA1 GP1BA